title: Practical Management of CD30⁺ Lymphoproliferative Disorders.
abstract: Primary cutaneous CD30⁺ lymphoproliferative disorders (LPDs) account for approximately 25% of cutaneous lymphomas. Although these LPDs are clinically heterogeneous, they can be indistinguishable histologically. Lymphomatoid papulosis rarely requires systemic treatment; however, multifocal primary cutaneous anaplastic large cell cutaneous lymphoma and large cell transformation of mycosis fungoides are typically treated systemically. As CD30⁺ LPDs are rare, there is little published evidence to support a specific treatment algorithm. Most studies are case reports, small case series, or retrospective reviews. This article discusses various treatment choices for each of the CD30⁺ disorders and offers practical pearls to aid in choosing an appropriate regimen.
authors.affiliation: University of Alabama at Birmingham, 1530 3rd Avenue South, EFH 414, Birmingham, AL 35294, USA. Electronic address: lchughey@uab.edu.
authors.forename: Lauren C
authors.initials: LC
authors.lastname: Hughey
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000473:pathology; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D006801:Humans; D017730:Ki-1 Antigen / Q000032:analysis; D054446:Lymphoma, Primary Cutaneous Anaplastic Large Cell / Q000145:classification / Q000473:pathology / Q000628:therapy*; D017731:Lymphomatoid Papulosis / Q000145:classification / Q000473:pathology / Q000628:therapy*; D009182:Mycosis Fungoides / Q000145:classification / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012878:Skin Neoplasms / Q000145:classification / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D017730:Ki-1 Antigen
keywords: CD30(+) cutaneous lymphoproliferative disorders; Lymphomatoid papulosis; Mycosis fungoides with large cell transformation; Primary cutaneous anaplastic large cell cutaneous lymphoma